간행물

대한간학회> Clinical and Molecular Hepatology(대한간학회지)

Clinical and Molecular Hepatology(대한간학회지) update

Clinical and Molecular Hepatology (CMH)

  • : 대한간학회
  • : 의약학분야  >  내과학
  • : KCI등재
  • : SCOPUS
  • : 연속간행물
  • : 계간
  • : 2287-2728
  • : 2287-285x
  • : 대한간학회지()→Korean Journal of Hepatology(2004~)→대한간학회지(2012~)

수록정보
수록범위 : 1권1호(1995)~28권4호(2022) |수록논문 수 : 4,815
Clinical and Molecular Hepatology(대한간학회지)
28권4호(2022년 10월) 수록논문
최근 권호 논문
| | | |

KCI등재 SCOPUS

저자 : Joong-won Park , Seung Up Kim

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 28권 4호 발행 연도 : 2022 페이지 : pp. 583-705 (123 pages)

다운로드

(기관인증 필요)

초록보기

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC. (Clin Mol Hepatol 2022;28:583-705)

KCI등재 SCOPUS

저자 : Youngseok Lee , Jong-hoon Kim

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 28권 4호 발행 연도 : 2022 페이지 : pp. 706-724 (19 pages)

다운로드

(기관인증 필요)

초록보기

Extracellular vesicles (EVs) are membrane-enclosed particles released from almost all cell types. EVs mediate intercellular communication by delivering their surface and luminal cargoes, including nucleic acids, proteins, and lipids, which reflect the pathophysiological conditions of their cellular origins. Hepatocytes and hepatic non-parenchymal cells utilize EVs to regulate a wide spectrum of biological events inside the liver and transfer them to distant organs through systemic circulation. The liver also receives EVs from multiple organs and integrates these extrahepatic signals that participate in pathophysiological processes. EVs have recently attracted growing attention for their crucial roles in maintaining and regulating hepatic homeostasis. This review summarizes the roles of EVs in intrahepatic and interorgan communications under different pathophysiological conditions of the liver, with a focus on chronic liver diseases including nonalcoholic steatohepatitis, alcoholic hepatitis, viral hepatitis, liver fibrosis, and hepatocellular carcinoma. This review also discusses recent progress for potential therapeutic applications of EVs by targeting or enhancing EV-mediated cellular communication for the treatment of liver diseases. (Clin Mol Hepatol 2022;28:706-724)

KCI등재 SCOPUS

저자 : Lei Miao , Jing Xu , Giovanni Targher , Christopher D Byrne , Ming-hua Zheng

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 28권 4호 발행 연도 : 2022 페이지 : pp. 725-738 (14 pages)

다운로드

(기관인증 필요)

초록보기

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM. (Clin Mol Hepatol 2022;28:725-738)

KCI등재 SCOPUS

저자 : Sang Jin Kim , Jong Man Kim

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 28권 4호 발행 연도 : 2022 페이지 : pp. 739-753 (15 pages)

다운로드

(기관인증 필요)

초록보기

Liver transplantation (LT) is one of the most effective treatments for hepatocellular carcinoma (HCC). Although LT eliminates HCC and greatly reduces recurrence, some patients experience recurrence after LT. Criteria and models for screening patients with a high probability of HCC recurrence after LT, starting with the Milan criteria, have been published. These models have changed over time, but a standard has not been established. We summarized HCC prediction models after LT by focusing on the application of radiologic, serologic, and pathologic factors and recent trends. This review will look at studies that are based on living donor LT and deceased donor LT, as well as studies that downstaging procedures have been performed preoperatively. This ultimately aims to help make decisions for evaluating the HCC state and selecting candidates for LT according to the circumstances of each transplantation center. (Clin Mol Hepatol 2022;28:739-753)

KCI등재 SCOPUS

저자 : Sung Hak Lee , Hyun-jong Jang

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 28권 4호 발행 연도 : 2022 페이지 : pp. 754-772 (19 pages)

다운로드

(기관인증 필요)

초록보기

Molecular tests are necessary to stratify cancer patients for targeted therapy. However, high cost and technical barriers limit the application of these tests, hindering optimal treatment. Recently, deep learning (DL) has been applied to predict molecular test results from digitized images of tissue slides. Furthermore, treatment response and prognosis can be predicted from tissue slides using DL. In this review, we summarized DL-based studies regarding the prediction of genetic mutation, microsatellite instability, tumor mutational burden, molecular subtypes, gene expression, treatment response, and prognosis directly from Hematoxylin and Eosin-stained tissue slides. Although performance needs to be improved, these studies clearly demonstrated the feasibility of DL-based prediction of key molecular features in cancer tissues. With the accumulation of data and technical advances, the performance of the DL system could be improved in the near future. Therefore, we expect that DL could provide cost- and time-effective alternative tools for patient stratification in the era of precision oncology. (Clin Mol Hepatol 2022;28:754-772)

KCI등재 SCOPUS

저자 : Hwang Sik Shin , Baek Gyu Jun , Sang-wook Yi

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 28권 4호 발행 연도 : 2022 페이지 : pp. 773-789 (17 pages)

다운로드

(기관인증 필요)

초록보기

Despite the increasing prevalence of metabolic disorders, the potential effects of metabolic factors on hepatocellular carcinoma (HCC) development in individuals with chronic liver diseases (CLDs) are not well understood. For a metabolic factor to be identified as a risk factor for HCC in patients with CLDs, such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, there should be a strong synergistic interaction between the carcinogenic mechanisms of the metabolic factor and the CLD itself. This review aims to comprehensively summarize the published data on the relationship between metabolic factors such as diabetes mellitus (DM), obesity, and blood lipids and the risk of HCC in patients with CLDs. DM consistently increases the risk of HCC in patients with CLD. When associated with DM, the risk of HCC seems to be highest in HCV and non-alcoholic fatty liver disease (NAFLD), followed by alcoholic liver disease (ALD) and HBV. Obesity may increase the risk of HCC. Among CLDs, the evidence is relatively consistent and clear for ALD, while clear evidence is limited in other CLDs including HBV, HCV, and NAFLD. Total cholesterol, potentially low-density lipoprotein cholesterol and triglyceride, seems to have strong inverse associations with HCC in individuals with CLDs. Despite evidence from observational studies, statins had no effect in preventing HCC in randomized controlled trials. Whether statins have a preventive effect against HCC is unclear. A better understanding and management of metabolic factors may be beneficial to reduce the risk of HCC in patients with CLDs. (Clin Mol Hepatol 2022;28:773-789)

KCI등재 SCOPUS

저자 : Cheng Han Ng , Daniel Q. Huang , Mindie H. Nguyen

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 28권 4호 발행 연도 : 2022 페이지 : pp. 790-801 (12 pages)

다운로드

(기관인증 필요)

초록보기

Nonalcoholic fatty liver disease (NAFLD) affects about a third of the world's adult population and is a major public health concern. NAFLD is defined by the presence of hepatic steatosis and the absence of other causes of liver disease. As NAFLD is closely associated with the presence of the metabolic syndrome, several experts have called for a change in nomenclature from NAFLD to metabolic-associated fatty liver disease (MAFLD) to better reflect the underlying pathophysiology of NAFLD as a metabolically driven disease and shift to a “positive” diagnostic criteria rather than one of exclusion. Recent studies have suggested that the global prevalence of MAFLD is higher than that of NAFLD, and patients with MAFLD have more metabolic comorbidities compared to those with NAFLD. Emerging data also suggest that all-cause and cardiovascular mortality may be higher in MAFLD compared with NAFLD. In this synopsis, we discuss differences in clinical features, prevalence and clinical outcomes between NAFLD and MAFLD. In addition, we highlight the advantages and disadvantages of a name change from NAFLD to MAFLD from the perspective of the scientific community, care providers and patients. (Clin Mol Hepatol 2022;28:790-801)

KCI등재 SCOPUS

저자 : Soon Sun Kim , Jae Youn Cheong

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 28권 4호 발행 연도 : 2022 페이지 : pp. 802-805 (4 pages)

다운로드

(기관인증 필요)

초록보기

KCI등재 SCOPUS

저자 : Carlos J. Pirola , Silvia Sookoian

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 28권 4호 발행 연도 : 2022 페이지 : pp. 806-809 (4 pages)

다운로드

(기관인증 필요)

초록보기

KCI등재 SCOPUS

저자 : Bo Hyun Kim , Yuri Cho , Joong-won Park

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 28권 4호 발행 연도 : 2022 페이지 : pp. 810-813 (4 pages)

다운로드

(기관인증 필요)

초록보기
123
권호별 보기

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기